Processa Pharmaceuticals, Inc.

next-generation chemotherapy and small molecule pharmaceuticals

PCSA · Nasdaq · United States

Share price · PCSA

$1.70-0.40 (-19.05%) 3M

close as of 2026-11-18 · 24h delayed · vol 30K (0.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PCSA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 12 Oct 2026+25.0%

    Nothing announced by PCSA that day or the session before.

  2. 29 Jul 2026-33.4%
  3. 28 Jul 2026+17.8%

    Nothing announced by PCSA that day or the session before.

  4. 22 Jul 2026+13.4%

    Nothing announced by PCSA that day or the session before.

  5. 11 Jun 2026+19.7%

    Nothing announced by PCSA that day or the session before.

  6. 9 Jun 2026-15.9%

    Nothing announced by PCSA that day or the session before.

  7. 2 Jun 2026+15.4%

    Nothing announced by PCSA that day or the session before.

  8. 14 May 2026+20.4%

    Nothing announced by PCSA that day or the session before.

  9. 19 Mar 2026-26.3%

    Nothing announced by PCSA that day or the session before.

  10. 18 Dec 2025-41.6%

Share of unusual movement by asset

For each asset, the share of PCSA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
PCS499
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—50%
Sessions with no dated event—50%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
PCS499No recent activity
Phase 2
—Small molecule
Necrobiosis Lipoidica

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$1.8M$180M$183M-$5.2M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$0.7M$0.2M$3.3M-$2.0M operating cash flowreport ↗
2026-Q1—$1.8M$1.7M$3.4M-$3.6M operating cash flowreport ↗
2025-Q3—$1.7M$6.3M$3.4M-$3.5M operating cash flowreport ↗
2025-Q2—$2.5M$6.9M$3.9M-$2.3M operating cash flowreport ↗
2025-Q1—$1.6M$2.9M$2.8M-$2.7M operating cash flowreport ↗
2024-Q3—$2.3M$2.9M$3.4M-$3.6M operating cash flowreport ↗
2024-Q2—$1.7M$5.6M$3.0M-$3.4M operating cash flowreport ↗
2024-Q1—$1.5M$8.9M$2.7M-$2.0M operating cash flowreport ↗
2023-Q3—$1.1M$6.9M$2.1M-$1.8M operating cash flowreport ↗
2023-Q2—$1.7M$8.7M$2.6M-$2.1M operating cash flowreport ↗
2023-Q1$0$1.6M$11M$4.0M-$2.1M operating cash flowreport ↗
2022-Q3—$3.1M$9.1M$6.0M-$3.0M operating cash flowreport ↗
2022-Q2—$3.1M$12M$5.2M-$2.3M operating cash flowreport ↗
2022-Q1$0$2.0M$14M$3.2M-$1.8M operating cash flowreport ↗
2021-Q3—$1.7M$19M$3.0M-$1.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$7.8M$5.5M$3.4M-$11M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$7.3M$1.2M$3.0M-$11M operating cash flowreport ↗
2023-FY—$5.8M$4.7M$2.8M-$8.1M operating cash flowreport ↗
2022-FY$0$11M$6.5M$6.9M-$9.6M operating cash flowreport ↗
2021-FY$0$6.9M$17M$2.9M-$8.7M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 45 purchases ($225K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-08Ng George K · director, Chief Executive OfficerOption exercise1,600——Form 4
2026-08-08Ng George K · director, Chief Executive OfficerOption exercise (derivative)1,600——Form 4
2026-07-28GUJRATHI SHEILA · directorAward / grant (derivative)70,811.877——Form 4
2026-07-28GUJRATHI SHEILA · directorAward / grant (derivative)12,311.279——Form 4
2026-07-26Baluch Khoso · directorAward / grant (derivative)33,500——Form 4
2026-07-26Guy Wendy · Chief Administrative OfficerAward / grant (derivative)9,450——Form 4
2026-07-26Lin Patrick · Chief Business - Strategy OffAward / grant (derivative)8,450——Form 4
2026-07-26Neal James R · directorAward / grant (derivative)62,221——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 10 reporting institutions held 0.2M shares ($448K, 6.4% of shares outstanding).

#InstitutionSharesValue
1Connective Capital Management, LLC70,736$179K
2Stonepine Capital Management, LLC55,000$139K
3GEODE CAPITAL MANAGEMENT, LLC24,908$63K
4VANGUARD CAPITAL MANAGEMENT LLC12,729$32K
5VANGUARD FIDUCIARY TRUST CO10,857$27K
6UBS Group AG2,531$6K
7Tower Research Capital LLC (TRC)918$2K
8CITIGROUP INC14$35
9JONES FINANCIAL COMPANIES LLLP7$17
10WELLS FARGO & COMPANY/MN6$15